A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 600 participants.

Also called NCT06972472

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 600 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06972472
  • EU CT 2025-521098-14-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, China, Czechia, Germany, Japan, Puerto Rico (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06972472. Randomized; double masking; primary purpose treatment. Start 2025-05-19 (actual); primary completion 2027-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Condition
Obesity
Condition
Overweight
Intervention (Drug)
Orforglipron
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct06972472
Content hash
ed0c0fbde370657478a750812d36a5951919960fae2b5106f3a73d9bc1eba8b7